Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL5859288 | 0.89 | PTGS1 (0.68) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| Carbamic Acid SCHEMBL5857953 | 0.89 | PTGS2 (0.73) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| SCHEMBL5673693 | 0.86 | PTGS2 (0.68) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| Carbamic Acid SCHEMBL5860891 | 0.85 | PTGS2 (0.69) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| SCHEMBL2697947 | 0.85 | PDPK1 (0.69) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| SCHEMBL14747805 | 0.84 | PTGS2 (0.74) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| Carbamic Acid SCHEMBL5859120 | 0.84 | PTGS2 (0.68) | PTGS1PTGS2PDPK1MAPTNR3C2 | |
| Carbamic Acid SCHEMBL5857933 | 0.84 | PTGS1 (0.64) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| SCHEMBL6451398 | 0.83 | PTGS1 (1.00) | PTGS1PTGS2PDPK1MAPTNR3C2 | |
| SCHEMBL2695594 | 0.82 | PDPK1 (0.71) | PTGS1CYP2C9PTGS2PDPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142368-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MRDC | 2006-06-29 | — | — | US | disclosed |
| US-7026346-B2 | Compounds and methods for inducing apoptosis in proliferating cells | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-20030236294-A1 | Compounds and methods for inducing apoptosis in proliferating cells | NIH - DEITR | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236294-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MCL1, BRDT, BAD | PTGS1 298/4885CYP2C9 4279/4885PTGS2 392/4885 |
| US-20060142368-A1 | Compounds and methods for inducing apoptosis in proliferating cells | MCL1, BRDT, BAD | PTGS1 303/4885CYP2C9 4297/4885PTGS2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.